Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9944844 | 0.91 | ALDH1A1 (0.45) | ALDH1A1MAPTNPSR1LMNANPC1 | |
| SCHEMBL9944838 | 0.88 | ALDH1A1 (0.39) | ALDH1A1MAPTNPSR1LMNANPC1 | |
| SCHEMBL9944996 | 0.83 | EZH2 (0.37) | ALDH1A1MAPTNPSR1POLBPTGES | |
| SCHEMBL9944903 | 0.82 | ALDH1A1 (0.42) | ALDH1A1MAPTNPSR1LMNANPC1 | |
| SCHEMBL9944988 | 0.76 | NPC1 (0.44) | ALDH1A1MAPTNPC1RAB9AHTT | |
| SCHEMBL9944775 | 0.76 | TDP1 (0.50) | ALDH1A1MAPTNPSR1LMNANPC1 | |
| SCHEMBL9944852 | 0.75 | HCAR3 (0.46) | ALDH1A1MAPTNPSR1LMNAHTT | |
| SCHEMBL9945008 | 0.74 | LMNA (0.39) | ALDH1A1MAPTLMNANPC1RAB9A | |
| SCHEMBL9944808 | 0.74 | KMT2A (0.46) | ALDH1A1MAPTHTT | |
| SCHEMBL9944993 | 0.74 | ALDH1A1 (0.40) | ALDH1A1MAPTLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | ALDH1A1 126/4885MAPT 4336/4885NPSR1 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.